Codexis Inc
NASDAQ:CDXS
Intrinsic Value
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. [ Read More ]
The intrinsic value of one CDXS stock under the Base Case scenario is 3.69 USD. Compared to the current market price of 2.65 USD, Codexis Inc is Undervalued by 28%.
Valuation Backtest
Codexis Inc
Run backtest to discover the historical profit from buying and selling CDXS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Codexis Inc
Current Assets | 93.5m |
Cash & Short-Term Investments | 65.1m |
Receivables | 19.9m |
Other Current Assets | 8.4m |
Non-Current Assets | 43.1m |
Long-Term Investments | 9.7m |
PP&E | 28.6m |
Intangibles | 2.5m |
Other Non-Current Assets | 2.3m |
Current Liabilities | 35.8m |
Accounts Payable | 5.9m |
Accrued Liabilities | 19.8m |
Other Current Liabilities | 10.1m |
Non-Current Liabilities | 14.1m |
Other Non-Current Liabilities | 14.1m |
Earnings Waterfall
Codexis Inc
Revenue
|
70.1m
USD
|
Cost of Revenue
|
-12.8m
USD
|
Gross Profit
|
57.3m
USD
|
Operating Expenses
|
-112.1m
USD
|
Operating Income
|
-54.8m
USD
|
Other Expenses
|
-21.4m
USD
|
Net Income
|
-76.2m
USD
|
Free Cash Flow Analysis
Codexis Inc
CDXS Profitability Score
Profitability Due Diligence
Codexis Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Codexis Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
CDXS Solvency Score
Solvency Due Diligence
Codexis Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Codexis Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDXS Price Targets Summary
Codexis Inc
According to Wall Street analysts, the average 1-year price target for CDXS is 6.7 USD with a low forecast of 3.03 USD and a high forecast of 10.5 USD.
Ownership
CDXS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CDXS Price
Codexis Inc
Average Annual Return | -5.02% |
Standard Deviation of Annual Returns | 59.78% |
Max Drawdown | -96% |
Market Capitalization | 185.2m USD |
Shares Outstanding | 70 303 600 |
Percentage of Shares Shorted | 3.46% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).
Contact
IPO
Employees
Officers
The intrinsic value of one CDXS stock under the Base Case scenario is 3.69 USD.
Compared to the current market price of 2.65 USD, Codexis Inc is Undervalued by 28%.